SG10201705880QA - Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same - Google Patents

Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same

Info

Publication number
SG10201705880QA
SG10201705880QA SG10201705880QA SG10201705880QA SG10201705880QA SG 10201705880Q A SG10201705880Q A SG 10201705880QA SG 10201705880Q A SG10201705880Q A SG 10201705880QA SG 10201705880Q A SG10201705880Q A SG 10201705880QA SG 10201705880Q A SG10201705880Q A SG 10201705880QA
Authority
SG
Singapore
Prior art keywords
env
hiv
envelope
methods
same
Prior art date
Application number
SG10201705880QA
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of SG10201705880QA publication Critical patent/SG10201705880QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201705880QA 2013-01-07 2014-01-07 Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same SG10201705880QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361749737P 2013-01-07 2013-01-07

Publications (1)

Publication Number Publication Date
SG10201705880QA true SG10201705880QA (en) 2017-08-30

Family

ID=51062514

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201505229XA SG11201505229XA (en) 2013-01-07 2014-01-07 Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
SG10201705880QA SG10201705880QA (en) 2013-01-07 2014-01-07 Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201505229XA SG11201505229XA (en) 2013-01-07 2014-01-07 Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same

Country Status (18)

Country Link
US (4) US9932370B2 (en)
EP (1) EP2983686B1 (en)
JP (1) JP6357487B2 (en)
KR (1) KR102020758B1 (en)
CN (1) CN105263506B (en)
AP (1) AP2015008634A0 (en)
AU (2) AU2014203886B2 (en)
CA (1) CA2897059C (en)
EA (1) EA030983B1 (en)
HK (1) HK1214509A1 (en)
IL (1) IL239805A (en)
MX (1) MX2015008815A (en)
MY (1) MY187152A (en)
NZ (1) NZ710727A (en)
PH (1) PH12015501526B1 (en)
SG (2) SG11201505229XA (en)
WO (1) WO2014107744A1 (en)
ZA (1) ZA201505608B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
EP3335728B8 (en) 2008-10-10 2020-03-11 Children's Medical Center Corporation Biochemically stabilized hiv-1 env trimer vaccine
AP2015008634A0 (en) 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US10716845B2 (en) 2013-10-04 2020-07-21 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
JP2017507672A (en) * 2014-02-28 2017-03-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Replicative recombinant adenoviral vectors, compositions and methods of use thereof
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
EP3197489B1 (en) * 2014-09-26 2021-02-17 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
MA40783A (en) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc HIV VACCINES CONTAINING ONE OR MORE POPULATION EPISENSUS ANTIGENS
WO2016105492A1 (en) * 2014-12-24 2016-06-30 Duke University Compositions comprising ch505 envelopes, and trimers (eight valent hiv-1 composition and methods)
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
LT3390430T (en) 2015-12-15 2019-11-25 Janssen Vaccines & Prevention Bv Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EP3426353A4 (en) * 2016-03-09 2020-05-06 The University of Massachusetts Use of modified hiv-1 for generating fully human antibodies
BR112018072248A2 (en) 2016-05-02 2019-02-12 The Scripps Research Institute compositions and methods related to hiv-1 immunogens
EA201892735A1 (en) * 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. COMPOSITION OF VACCINE AGAINST HIV
CN110494159A (en) 2016-09-02 2019-11-22 扬森疫苗与预防公司 Method of the induction for the immune response of HIV infection in the object of antiretroviral therapy
EP3512543B1 (en) 2016-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations
EP3526236A4 (en) 2016-10-17 2020-06-03 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
BR112019026126A2 (en) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. poxvirus vectors encoding HIV antigens and methods of using them
MA49616A (en) 2017-07-19 2020-05-27 Janssen Vaccines & Prevention Bv TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
AU2018358238B2 (en) 2017-11-01 2022-08-18 The Scripps Research Institute Novel scaffolded HIV-1 vaccine immunogens
WO2019226829A1 (en) 2018-05-22 2019-11-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
EP3807210A4 (en) 2018-06-13 2022-05-11 The Scripps Research Institute Nanoparticle vaccines with novel structural components
EP3856238A1 (en) 2018-09-25 2021-08-04 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
TW202110476A (en) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2021089770A2 (en) 2019-11-07 2021-05-14 Janssen Vaccines & Prevention B.V. Protein purification
EP4090348A4 (en) * 2020-01-13 2024-05-15 Univ California Methods for treating viral infections
KR20220002156A (en) * 2020-06-30 2022-01-06 포항공과대학교 산학협력단 Kit for screening for therapeutic agent for preventing or treating Corona-virus infection by using of esterase activity of Corona-19 virus spike protein and pharmaceutical composition comprising material selected therefrom
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
WO1992015672A1 (en) 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
CA2505583C (en) 2002-12-03 2014-07-15 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
US20080274134A1 (en) 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
AU2005274948B2 (en) 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
WO2006040330A2 (en) 2004-10-13 2006-04-20 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
WO2007005934A2 (en) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (en) 2005-08-23 2011-02-09 加利福尼亚大学董事会 Polyvalent vaccine
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
CA2655934A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
CA2667358A1 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
EP3335728B8 (en) * 2008-10-10 2020-03-11 Children's Medical Center Corporation Biochemically stabilized hiv-1 env trimer vaccine
CN102282175B (en) 2008-11-18 2015-09-30 贝斯以色列护理医疗中心 There is the antiviral vaccine of the cell immunogenicity of improvement
EP4226935A3 (en) 2010-08-31 2023-09-06 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst An hiv-1 gp120 mini v3 loop and uses thereof
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
CA3200425A1 (en) 2012-11-16 2014-05-22 Peter ABBINK Recombinant adenoviruses and use thereof
AP2015008634A0 (en) 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
JP6594306B2 (en) 2013-07-08 2019-10-23 ノバルティス アーゲー Rotavirus particles with chimeric surface proteins
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
TWI617156B (en) 2013-09-30 2018-03-01 高通公司 Short packet communication in a powerline communication network
US10716845B2 (en) 2013-10-04 2020-07-21 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same

Also Published As

Publication number Publication date
WO2014107744A1 (en) 2014-07-10
US9932370B2 (en) 2018-04-03
IL239805A (en) 2017-11-30
EP2983686A1 (en) 2016-02-17
EA201591287A1 (en) 2015-12-30
ZA201505608B (en) 2018-11-28
PH12015501526A1 (en) 2015-09-21
EP2983686B1 (en) 2024-05-29
SG11201505229XA (en) 2015-08-28
EA030983B1 (en) 2018-10-31
CN105263506B (en) 2018-03-09
US20210317169A1 (en) 2021-10-14
US11059863B2 (en) 2021-07-13
NZ710727A (en) 2020-03-27
CN105263506A (en) 2016-01-20
KR20150118131A (en) 2015-10-21
US20140302080A1 (en) 2014-10-09
MY187152A (en) 2021-09-06
AU2018200696A1 (en) 2018-02-22
AU2014203886B2 (en) 2017-11-02
US20180186839A1 (en) 2018-07-05
JP2016503819A (en) 2016-02-08
MX2015008815A (en) 2016-10-26
US20190055290A1 (en) 2019-02-21
JP6357487B2 (en) 2018-07-11
CA2897059A1 (en) 2014-07-10
KR102020758B1 (en) 2019-09-11
EP2983686A4 (en) 2016-09-14
IL239805A0 (en) 2015-08-31
AU2014203886A1 (en) 2015-08-20
CA2897059C (en) 2021-12-28
AP2015008634A0 (en) 2015-07-31
US10160788B2 (en) 2018-12-25
AU2018200696B2 (en) 2019-09-12
PH12015501526B1 (en) 2015-09-21
HK1214509A1 (en) 2016-07-29

Similar Documents

Publication Publication Date Title
HK1214509A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same (hiv)(env)
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
ZA201700165B (en) Influenza virus vaccines and uses thereof
EP3052518A4 (en) Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
EP3052132A4 (en) Antibody therapies for human immunodeficiency virus (hiv)
HK1223110A1 (en) Influenza virus vaccines and uses thereof
SG11201610443WA (en) Influenza virus vaccines and uses thereof
EP3526236A4 (en) Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
EP3273990A4 (en) Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
EP3303370A4 (en) T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
HK1206940A1 (en) Microemulsion preconcentrates and microemulsions, and preparation processes of the same
HK1201283A1 (en) Influenza c virus and vaccine
EP2632942A4 (en) Recombinant envelope protein of human immunodeficiency virus (hiv) and vaccine containing the same
EP3211073A4 (en) Replicative vaccinia virus vector hiv vaccine
TH1501003876A (en) Vaccine of the enveloped trimer (Env) of human immunodeficiency virus. Stabilizing human immunodeficiency virus (HIV) and methods of use are the same.
IL249704A0 (en) Influenza virus vaccines and uses thereof
IL249705A0 (en) Influenza virus vaccines and uses thereof
GB201400760D0 (en) Use of geneticaly modified virus in order to remove viral latency shown on HIV example
GB201323103D0 (en) HIV vaccine and cure